Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MDNA.TOthis companyMedicenna Therapeutics Corp.	CA$0.44	-2.91×	21.45×	0×	-1.99×	-91.3%	0.0%	0.0%	0.0%	-741.7%	-725.4%	0.0%	0.05×	0.26×	0×	1.52×	0.0%	0	-30.04	2	C
ARCH.VArch Biopartners Inc.	CA$0.89	-54.01×	-21.63×	0×	-67.06×	-107.1%	0.0%	0.0%	0.0%	40.0%	145.7%	-1.9%	-0.73×	-2.19×	-5.88×	0.03×	0.0%	2	-1,107.49	2	C
BNXT.CNBioNxt Solutions Inc.	CA$0.26	-10.76×	-8.07×	0×	-13.49×	-121.0%	0.0%	0.0%	0.0%	75.0%	172.2%	-6.9%	-0.63×	-0.98×	-4.2×	0.05×	0.0%	3	-88.15	2	C
COV.VCovalon Technologies Ltd.	CA$4.31	27.96×	1.87×	1.75×	14.09×	-262.9%	53.2%	5.4%	6.3%	6.7%	5.3%	2.9%	0.07×	-5.02×	0×	8.36×	0.0%	7	15.85	4	A-
DTC.CNDefence Therapeutics Inc.	CA$0.36	-4×	7.79×	0×	-5.53×	-98.2%	0.0%	0.0%	0.0%	-190.7%	-94.2%	-17.4%	0.49×	0.03×	-12.15×	3.42×	0.0%	2	-5.63	1	C-
MDP.TOMedexus Pharmaceuticals Inc.	CA$5.13	-44.57×	2.06×	1.02×	9.21×	-84.1%	54.8%	5.9%	-2.4%	-4.9%	6.1%	3.7%	0.45×	1.24×	1.12×	1.19×	0.0%	5	1.26	2	C
Peer median	—	-10.76×	1.87×	0×	-5.53×	-107.1%	0.0%	0.0%	0.0%	6.7%	6.1%	-1.9%	0.07×	-0.98×	-4.2×	1.19×	0.0%	3	-5.63	2	—